Our results pave the way for the development of CRL4DCAF1-dependent PROTACs or molecular glue degraders (Levin-Kravets et al, 2021; Bekes et al, 2022) to target PLK4 degradation as a novel modality for cancer therapy. Here, PLK4 is linked to cancer.